Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
William Durante, Ghazaleh Behnammanesh, Kelly J. Peyton
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8786-8786
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 142
Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 24
Ischemia and no obstructive coronary arteries (INOCA): A narrative review
Puja K. Mehta, Jingwen Huang, Rebecca D. Levit, et al.
Atherosclerosis (2022) Vol. 363, pp. 8-21
Open Access | Times Cited: 55
Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia
Sharif A. Sabe, Cynthia Xu, Mohamed Sabra, et al.
Journal of the American Heart Association (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 41
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 36
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 35
SGLT2 inhibition ameliorates nano plastics-induced premature endothelial senescence and dysfunction
Bikalpa Dhakal, Saugat Shiwakoti, Eun‐Young Park, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study
Han Eol Jeong, Sohee Park, Yunha Noh, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 22
Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement
Fatmah R. Alsereidi, Zenith Khashim, Hezlin Marzook, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 5, pp. 102524-102524
Closed Access | Times Cited: 11
Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling
Jingjing Zhang, X. Ye, Xuesong Liu, et al.
World Journal of Cardiology (2025) Vol. 17, Iss. 1
Closed Access | Times Cited: 1
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Roko Škrabić, Marko Kumrić, Josip Vrdoljak, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2458-2458
Open Access | Times Cited: 36
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
Panagiotis Theofilis, Μarios Sagris, Evangelos Oikonomou, et al.
Diabetes Research and Clinical Practice (2022) Vol. 188, pp. 109927-109927
Closed Access | Times Cited: 29
A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory
Marcin Piechocki, Tadeusz Przewłocki, Piotr Pieniążek, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1508-1508
Open Access | Times Cited: 6
Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
Xiaoling Li, Benedikt Preckel, Jeroen Hermanides, et al.
British Journal of Pharmacology (2022) Vol. 179, Iss. 16, pp. 4047-4062
Open Access | Times Cited: 27
Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)
Cristina Andreea Adam, Razvan Anghel, Dragoș Traian Marius Marcu, et al.
Life (2022) Vol. 12, Iss. 6, pp. 803-803
Open Access | Times Cited: 27
Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction
Ivona Mustapić, Darija Baković, Zora Sušilović Grabovac, et al.
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 42-42
Open Access | Times Cited: 23
The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis
Panagiotis Stachteas, Paschalis Karakasis, Dimitrios Patoulias, et al.
Annals of Medicine (2023) Vol. 55, Iss. 2
Open Access | Times Cited: 15
The Era of Risk Factors Should End; the Era of Biologic Age Should Begin
Philip D Houck
Hearts (2025) Vol. 6, Iss. 1, pp. 2-2
Open Access
Sodium-glucose cotransporter-2 inhibitors in cardiovascular disease: a gaseous solution
William Durante
Medical Gas Research (2025) Vol. 15, Iss. 2, pp. 206-207
Closed Access
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
Elena Y. Rykova, Vadim V. Klimontov, Elena Kazakova, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1670-1670
Open Access
Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes
Francesco Piccirillo, Marina Lanciotti, Annunziata Nusca, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2103-2103
Open Access
Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats
Aline Bomfim Vieira, Sarah M. Cavanaugh, Bianca Torres Ciambarella, et al.
Frontiers in Veterinary Science (2025) Vol. 12
Open Access
Monitoring SGLT2 inhibition effectiveness on pulmonary systolic pressure in heart failure with reduced ejection fraction
Marco Stracqualursi, Giulia Nemola, Gloria Santangelo, et al.
International Journal of Cardiology (2025), pp. 133136-133136
Closed Access
Pharmacological Countermeasures for Long-Duration Space Missions: Addressing Cardiovascular Challenges and Advancing Space-Adapted Healthcare
Audrey Derobertmasure, Li Shean Toh, Virginia E. Wotring, et al.
European Journal of Pharmaceutical Sciences (2025) Vol. 209, pp. 107063-107063
Open Access
Empagliflozin demonstrates neuroprotective and cardioprotective effects by reducing ischemia/reperfusion damage in rat models of ischemic stroke and myocardial infarction
Wangde Dai, Rashid Alavi, Jiajun Li, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top